Drug Type Fusion protein |
Synonyms HLX318 |
Target |
Action agonists, inhibitors, modulators |
Mechanism BAFF agonists(B-cell-activating factor/B lymphocyte stimulator agonists), BCMA inhibitors(B-cell maturation protein inhibitors), TACI modulators(Tumor necrosis factor receptor superfamily member 13B modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Autoimmune Diseases | Preclinical | China | 25 Aug 2025 |






